NCT05192486View on ClinicalTrials.gov

A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Diffuse Large B-cell Lymphoma
Interventions
DRUG

GNC-038

Administration by intravenous infusion

Trial Locations (4)

200025

Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

Unknown

Shenzhen Second People's Hospital, Shenzhen

Affiliated Hospital of Hebei University, Baoding

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

All Listed Sponsors
collaborator

SystImmune Inc.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT05192486 - A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) | Biotech Hunter | Biotech Hunter